PedvaxHIB provides a full range of benefits

PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. PedvaxHIB should not be used in infants younger than 6 weeks of age.

Select safety information

PedvaxHIB is contraindicated in patients with hypersensitivity to any component of the vaccine. Persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.

The most frequently reported (>1%) adverse reactions, without regard to causality, were fever (>101°F), irritability, sleepiness, injection-site pain/soreness, injection-site erythema (<2.5 cm diameter), injection-site swelling/induration (<2.5 cm diameter), unusual high-pitched crying, prolonged crying (>4 hours), diarrhea, vomiting, crying, pain, otitis media, rash, and upper respiratory infection.

Before administering PedvaxHIB, please read the Prescribing Information.

Go to Antibody response or Dosing convenience.

References: 1. American Academy of Pediatrics Committee on Infectious Diseases. Haemophilus influenzae type b conjugate vaccines: recommendations for immunization with recently and previously licensed vaccines. Pediatrics. 1993;92:480–488. 2. Data available on request from Merck & Co., Inc., Professional Services—DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20703489(1)-PED.

PedvaxHIB is a registered trademark of Merck & Co., Inc.